[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638825":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":60,"collaborators":24,"id":62,"slug":24,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":24,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":24,"enrollmentInfo":70,"targetDuration":24,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Gilead Sciences","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a: Monotherapy Dose Escalation","EXPERIMENTAL","Participants will receive escalating doses of GS-2426 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 week, whichever occurs first.",[13],"Drug: GS-2426",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b: Monotherapy Dose Expansion","Participants will be enrolled in different indication-specific cohorts. Participants will receive GS-2426 monotherapy at the recommended dose until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 weeks, whichever occurs first.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","GS-2426","Administered Orally",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Gilead Study Director","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Gilead Clinical Study Information Center","CONTACT","1-833-445-3230 (GILEAD-0)","GileadClinicalTrials@gilead.com",[36,50],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":24},"START Astera, LLC","RECRUITING","East Brunswick","New Jersey","08816","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-74.41598,40.42788,{"lat":48,"lon":47},{"facility":51,"status":38,"city":52,"state":53,"zip":54,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":24},"START San Antonio, LLC","San Antonio","Texas","78229",{"type":45,"coordinates":56},[57,58],-98.49363,29.42412,{"lat":58,"lon":57},{"type":61,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100638825",false,"NCT07601243","Study of GS-2426 in Participants With Advanced Solid Tumors","A Phase 1, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Tolerability of GS-2426 in Participants With Advanced MTAP-Deleted Solid Tumors","Key Inclusion Criteria:\n\n* Participants 18 years of age or older (≥ 19 years old for participants in South Korea).\n* Histologically or cytologically confirmed advanced malignant solid tumors, who have progressed on, are intolerant to or are ineligible for standard therapy, or have no standard treatment options.\n* Participant tumors are methylthioadenosine phosphorylase (MTAP)-deficient.\n* Adequate organ function\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* All participants must provide a pretreatment tumor tissue sample.\n\nKey Exclusion Criteria:\n\n* Participants with plans to breastfeed during the study period or within 7 days following the last dose of study intervention.\n* Have not recovered (ie, returned to Grade 1 or baseline) from clinically significant adverse events (AEs) due to a previously administered agent or a previous intervention as assessed by the investigator.\n* Active second malignancy. Individuals with a history of malignancy who have been completely treated with no evidence of active cancer for 5 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence may be enrolled.\n* Requirement for ongoing therapy with any prohibited medications .\n* Prior therapy with a protein arginine methyltransferase 5 (PRMT5) inhibitor or methionine adenosine transferase 2a (MAT2A) inhibitor.\n* Have serious infection requiring antibiotics within 14 days prior to the first dose.\n* Uncontrolled concurrent diseases\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":71,"type":72},174,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors.\n\nThe primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)\u002Fmaximum administered dose (MAD) and the recommended phase II dose (RP2D).",[78],"Advanced Solid Tumors","2026-06-19",{"date":81,"type":82},"2026-06-24","ACTUAL",{"date":84,"type":82},"2026-06-02",{"date":86,"type":72},"2029-01",{"name":5,"class":6},2]